Addex Therapeutics: Financial Updates and Collaboration

Addex Therapeutics, a Swiss pharmaceutical company, is set to release its Third Quarter 2023 Financial Results and participate in the Bio-Europe 2023 Conference. The company's CEO and key executives will provide business updates and review the company's product pipeline, including their lead drug candidate ADX71149 in a Phase 2 clinical trial for epilepsy treatment. Additionally, the company has extended its collaboration agreement with Indivior PLC for the discovery of novel oral GABAB positive allosteric modulator drug candidates for substance use disorder, with Indivior committing CHF 2.7 million to support research and discovery activities.